Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression

15 Feb 2023

Abstract excerpt

Abstract Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination between HSCs and their neoplastic counterparts in MDS-derived bone marrows (MDS-BMs) remains challenging. We hypothesized that in MDS patients immature CD34+CD38− cells with aberrant expression of immunophenotypic markers reflect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36792658
DOI: 10.1038/s41375-023-01811-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progressionPMID 36792658Read ↗

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterationsSemantic proximity Read ↗

Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes.Semantic proximity Read ↗

Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cellsSemantic proximity Read ↗

Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.Semantic proximity Read ↗

The Use of Flow Cytometry in Myelodysplastic Syndromes: A ReviewSemantic proximity Read ↗

Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

The current and future role of stem cells in myelodysplastic syndrome therapies.Semantic proximity Read ↗

Stem cell concepts in myelodysplastic syndromes: lessons and challenges.Semantic proximity Read ↗

Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.Semantic proximity Read ↗

Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDSSemantic proximity Read ↗

Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?Semantic proximity Read ↗

Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.